{"name":"Ellipses Pharma","slug":"ellipses-pharma","ticker":"","exchange":"","domain":"ellipsespharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNd29peEtBTk1JZW1Jc3FiQUpCeS1qMVhCaVdJb1JNNE50Tl9UN3A4eDJ3bHpxVDJ5RW8wOVhPNVpqWmZNUDVra2dCdTREdEV2ZGlsNHFjOUlUTHo3TjNqRVh3MTNsdFNmR2VSWjB0dmVWQVVrWlNJZlR6ZzJ0SlhHUWNkNU9PZmR6WXdzRVNEYm9SYzF6WUNteWtpRlVsWjgxNGdTVlJwZDRrS2lWM0djNWpJQ2tZYjlZRmU1V1g2bw?oc=5","date":"2026-01-23","type":"deal","source":"European Biotechnology Magazine","summary":"London-based Ellipses licenses another oncologic asset from Chinese pharma - European Biotechnology Magazine","headline":"London-based Ellipses licenses another oncologic asset from Chinese pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPN1phMUktNGg5YjhBLVZHMGlvbFhxY1RFV09iRTRhejROVkNMb0IxRFNIU3otNHBpYjFOMUxvVjBHaDh0Y0w1R3lWLVZtNkYtMFNXUnpVdktRY2lpdjBxQnBTZ19NZGdITWFMWG9UNEE2Ukw0YWVvLV9tODZqMUlVWUV2RDdhbDg?oc=5","date":"2026-01-23","type":"deal","source":"The Pharma Letter","summary":"Ellipses in-licenses ADC from China - The Pharma Letter","headline":"Ellipses in-licenses ADC from China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPTVFMUVA1RFJZcUhfQmppRFFNQW5LMmdHUG5PNGVRVTFuNnVaQXYyOGdWdkF2dFdqQVNsNlZfOFhIbnBVRkMzeTI2Nnlfa0E2QUpQWFhxeFdiZDZ1akdxdlphV1RvMWJYY2IxaTBXbTJTeWRsclg4Z2Jncm4xQmxWSjBfWm9JUXBicENuSmNrcmh6ZGNfd2lWa2NLbms5bE1SZGsyQk5SMGxWaW52VC1IYmhoV0tWQQ?oc=5","date":"2026-01-23","type":"deal","source":"BioSpace","summary":"Ellipses In-Licenses First-in-Class B7H3 Antibody Drug Conjugate From China - BioSpace","headline":"Ellipses In-Licenses First-in-Class B7H3 Antibody Drug Conjugate From China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5XWUJWOURpQ2RjblNPZlVWX2NWYTRJNHZPVWdlNnhUZXF3Z3ZmRnMtRmRjWm5QN0xNVUZ6T0V2czdWbk5RZEVMLXN1VFg5aEpTU1ktUnRmUW9UM3VNWDcxSEZONzZpS1R4OWFHNzVCVng3Z1J5YmNKV1FkY1NQems?oc=5","date":"2026-01-22","type":"trial","source":"Oncology Pipeline","summary":"Ellipses Pharma widens its orbit | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Ellipses Pharma widens its orbit | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1kVEE0Q0ZGcHdvTHh2ZEE3aEhXa2FNUEZqck8zVjRaMEF1R2VfUW9QbnllVkcxYzM3LVBFZXhWbXpMdTNBZlh3QmtXQ1pfVkZSX0ZMNWVIVDVONzFxOGhZcg?oc=5","date":"2026-01-21","type":"pipeline","source":"Oncodaily","summary":"Ellipses Pharma Announces Exclusive Licence Agreement with Innolake Biopharm to Develop a First-in-Class B7H3-Targeted ADC - Oncodaily","headline":"Ellipses Pharma Announces Exclusive Licence Agreement with Innolake Biopharm to Develop a First-in-Class B7H3-Targeted A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOQTBSSHFfM1NZTkxsLThvcUJYcHBpT04yc3RHQ3RVSFFqUkhLWlRCQ1dmZnE0MFdzbkZrZ3d3SzVzRHM1N1FjTVF6RUF3WkdKN3h5MHNObEplc1RmS2liVVdvQnU2SEFQWjNoME8xUDM3aFFfUHpYcThzejV0aHRoTjdlTHZrbEVVTU5hQXkzNGJsZVJPWm9sRUZZd0NFak9ONHdqdVlSVG41MjhXVnVtaS1NNXE?oc=5","date":"2025-10-02","type":"pipeline","source":"Health Tech World","summary":"Kelun Biotech RET Inhibitor accepted for review by Chinese regulators - Health Tech World","headline":"Kelun Biotech RET Inhibitor accepted for review by Chinese regulators","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxORjNQV2JDSGt4UEtBeU1YR29JcHdlV1VlMDVGcnJhLS0xbTFpSXVHd2tZVjJwazh4SXRRUmF0V0FWQU9yOGxIUVdwTEkxNjNlQlUzdDRoV1JrNHVYSXZiM3pORnRiMHcxNzVtc3dFLXVYUmc4THpUbkRRZl9wYlB2dG0wVTdsR0FLZzlUdDBWbjllemlpWkVuMkdydWI4YTBHNWc?oc=5","date":"2025-06-04","type":"pipeline","source":"Sky News","summary":"Biotech king Evans lands $50m injection for Ellipses cancer drugs - Sky News","headline":"Biotech king Evans lands $50m injection for Ellipses cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPWnlMMEpDNk5pQ1U2cDN4MmtJcTJNMG5nY0g2bzJtV3F6ZVc0X0dTSDRyQTBFNFM3Y1FvMk1fWG4wbHRWVFdWRldicDJ4Umd1RmNqc2UyemtyejhYV0t5X1dlQWV2cU9GTlhfbVl4c2gyNUZBZ0ZCUGJpY2R3Y2tHcnRBRll1U0FDUE84Q3Y0S1JENVZFRWFZZGRB?oc=5","date":"2025-03-14","type":"pipeline","source":"The Pharma Letter","summary":"Ellipses Pharma: the drug development model that minimizes risk - The Pharma Letter","headline":"Ellipses Pharma: the drug development model that minimizes risk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE8tQmUyYWx4bGQ3bzlaZmlrZ1RveEYxRU5UeU9pQjF3X2hwTEFwalZ5ZXdkYm5XR2Jxb3JIT0trelU1dTdYWnk0ZkNoS2dCRWRadDBTSWVCMG9wSW1LaFVZNGdCU3o0NXRLaFEzdnlR0gFyQVVfeXFMTVAyTlE0bzNsWm52dUw4NWdjVWpoMmpZWjA5OENKNkw0UTkyVTdiUEEySXA0T1FHUUVFMzhUR21UeXJPdmdvMTk2eVhpS2xERENNOEVqczB1TkFMSjhCTEZPN0lmRTZvbE9Ib3huNUh3Qk5B?oc=5","date":"2025-02-12","type":"deal","source":"koreabiomed.com","summary":"Genome & Company licenses out immunotherapy GENA-104 to UK’s Ellipses Pharma for global development - koreabiomed.com","headline":"Genome & Company licenses out immunotherapy GENA-104 to UK’s Ellipses Pharma for global development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNXzFNRkpyTWl1SFMza2V4MWw5WEtUSkNmS2FoYWtDOE1HcEpIc2t6OUNvank4eXZIbF9JcWE4dUVVZWdxekF5c2RCMEhjcllRaGxOdFVSYWNCSlFhM3UwRlpxckFqY2hfUmx3dEdRLXRCMVJ3ZXdDUjNkUmlLSHpacy0yaUR3cnZpc01XYzV3dEtKbDYwNHhrZzZEVlhrNzNvdjNmMGZUZDIwU3hTLVJrNG9xUXF1OFlnX3U4akdScjBueUVMankwVVdPbGhTdw?oc=5","date":"2024-12-23","type":"trial","source":"BioPharma APAC","summary":"Ellipses Pharma Launches Middle East’s First Large-Scale Oncology Phase 1/2 Clinical Study - BioPharma APAC","headline":"Ellipses Pharma Launches Middle East’s First Large-Scale Oncology Phase 1/2 Clinical Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNWx0TWpCc2xhVjVld0Q5VzlVQ2dGcExkaGo2UkhUSU1tR2kzNFV4TWpjaTdoamh5UXNZRVBpbC00MmVSZ0t2amFBNllzcVdzQzhZenczQ0xNcEphLXByNWpWZmgwSmxKT1FseTFwSC1JRC10RUhkS0wtN3p5SUhjaWlURVRmYzkxVERwQ0hxaVNaQWxfMDIzeTY4aEw4RUlSQm9qQWdOQ2Z4OTZKcUdpVGlmWl8zSk82aXZuYm9yT015YVU?oc=5","date":"2024-12-22","type":"trial","source":"Business Wire","summary":"Ellipses Launches Pioneering Clinical Trial Programme in Middle East - Business Wire","headline":"Ellipses Launches Pioneering Clinical Trial Programme in Middle East","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9sY0NzOE82aDduS244ZTgydGtJeER6MHpaQkdYWGhtX0pueDgwaThCN2FKeTVmelZTTjFwc2tLcGpleERESmhUemIzbkVKWV9TVnZDRWQ0X0JrVVVQNmZV?oc=5","date":"2023-03-21","type":"pipeline","source":"nature.com","summary":"Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D - nature.com","headline":"Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}